GGHC
PETX

Gilder Gagnon Howe & Co’s Aratana Therapeutics, Inc. PETX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,368
Closed -$68K – 316
2014
Q2 		$68K Buy
+4,368
New +$61.9K ﹤0.01% 281

Other funds holding PETX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Gilder Gagnon Howe & Co's PETX Position: Q3 2014 in Review

Gilder Gagnon Howe & Co sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2014, closing a stake of 4,368 shares — an estimated $68K sold.

Gilder Gagnon Howe & Co first reported a position in PETX in Q2 2014 and held it in 1 quarter. The position peaked at $68K in Q2 2014. 82 funds tracked by Wall St. Rank hold PETX as of Q3 2014.

  • Gilder Gagnon Howe & Co reported no remaining Aratana Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 4,368 Aratana Therapeutics, Inc. shares in Q3 2014, an estimated $68K.
  • Gilder Gagnon Howe & Co first reported a position in Aratana Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Aratana Therapeutics, Inc. position peaked at $68K in Q2 2014.
  • 82 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2014.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2014, filed 13 Nov 2014.